Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Phio Pharmaceuticals ( (PHIO) ) is now available.
Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, with over 30 years of experience in investment banking and asset management, will serve on the Board’s Nominating Committee. This strategic appointment is expected to bolster Phio’s capabilities as it advances its gene silencing technology in the biopharma sector, particularly in immuno-oncology therapeutics.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing therapeutics using its INTASYL siRNA gene silencing technology. This technology is designed to enhance the immune system’s ability to kill cancer cells, targeting and silencing genes with high specificity across various cell types and tissues. Phio’s lead program, PH-762, is an INTASYL compound aimed at treating skin cancers, currently in a Phase 1b trial.
YTD Price Performance: -8.42%
Average Trading Volume: 6,674,734
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $8.12M
See more insights into PHIO stock on TipRanks’ Stock Analysis page.